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UNLIKELY SPLICING: THE MYRIAD DECISION,
THE GENOMIC RESEARCH AND ACCESSIBILITY




"Last week, a federal judge threw out patents on two genes linked to
cancer," declared comedian and satirist Stephen Colbert on his television
show, The Colbert Report, in early 2010.1 "This is a huge blow to the
biotech industry," because, after all, "why cure cancer if you can't make a
buck off of it?" 2 Colbert then expressed concern over the ruling's effect on
his own patented genetic material, which he had supposedly planned to sell,
and worried that "anyone could make a cheap knockoff."3 Levity aside, the
issue of gene patenting is a complex matter that defies simplistic analysis
and could significantly affect the future development of life-saving
therapeutics. The United States Department of Justice ("DOJ") has stated
that the issue of patenting basic discoveries in genetics "is a question of
great importance to the national economy, to medical science, and to the
public health."4
The case mentioned by Colbert is Ass'n for Molecular Pathology v.
United States Patent and Trademark Office ("Myriad 1"), which was
subsequently overturned in part by the United States Court of Appeals for
* J.D. Candidate, The Catholic University of America, Columbus School of Law, May
2012. The author is grateful for helpful feedback from Professor Megan La Belle, Jason
Ferrone, and Joseph Kovacs. The author would like to thank the editors and staff of the
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1. The Colbert Report: Formula 01 Liquid Genetic Material (Comedy Central




4. Brief for the United States as Amici Curiae in Support of Neither Party at 1,
Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329 (Fed.
Cir. 2011) (No. 2010-1406), 2010 WL 4853320 at *1 [hereinafter DOJ Brief|.
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the Federal Circuit ("CAFC").5 However, the battle in the courts is only one
front of a concerted campaign against gene patenting. In the halls of
Congress, there is an interconnected movement working to pass legislation
to ban any further patenting of human genetic material. What the scope of
this ban should be and how it should be implemented are questions that have
aroused great contention.
Congressman Xavier Becerra has previously proposed, and currently
plans to reintroduce, the Genomic Research and Accessibility Act
("GRAA"), a bill that, if enacted, would place a broad prohibition on the
6patenting of any human genetic material. Opponents fear that the
indeterminate language of the bill would inhibit production of cutting-edge
biotechnology innovations, which offer great promise in combating genetic
7diseases. Among the most promising of these threatened innovations are
antisense drugs, which are short strands of modified DNA and RNA
specifically designed to combat genetic disorders by inhibiting the synthesis
of disease-causing proteins within the human body.8 The possible negative
effects of the GRAA would fall most heavily on those who suffer from
orphan diseases, because most pharmaceutical companies do not consider
developing drugs to treat these rare diseases to be commercially viable.9
This Note begins by outlining how the U.S. Patent and Trademark Office
("USPTO") and the federal courts determine what constitutes patentable
subject matter. Next, this Note describes the burgeoning knowledge of the
human genome, and the race to patent the BRCAl and BRCA2 (Breast
Cancer Susceptibility) genes. The patenting of these breast cancer genes is
at the root of the potentially landmark Myriad I case, which dramatically
upended patent law in 2010, until it was overturned by the CAFC in mid-
5. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriadl"), 702 F. Supp. 2d 181 (S.D.N.Y. 2010), aff'd in part, rev'd in part, 653 F.3d
1329 (Fed. Cir. 2011).
6. Genomic Research and Accessibility Act, H.R. 977, 1 10th Cong. (2007).
7. Letter from Sharon F. Terry, President and CEO, Genetic Alliance, to Xavier
Becerra, U.S. Representative from California (Feb. 3, 2011) (on file with author).
8. Zina Moukheiber, Antisense and Sensibility, FORBES.COM (Apr. 1, 2002),
http://www.forbes.com/forbes/2002/0401/120.html (stating "[aintisense drugs are named
after the two strands of DNA that form the double-helix structure, which are known as
sense and antisense").
9. See J.K. Aronson, Rare Diseases and Orphan Drugs, 61 BRIT. J. CLIN.
PHARMACOLOGY 243, 244 (2006).
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2011. This Note argues that the structure of federal regulation of the
pharmaceutical industry unwittingly aggravated the existing problem of rare
diseases. While the Orphan Drug Act of 1983 has partially alleviated the
situation, its success has been dependent on private sector investment and
innovation that have greatly aided those suffering from rare diseases. This
Note makes the case that Judge Sweet's Myriad I holding and the proposed
GRAA are inappropriate tools to solve the perceived problem of gene
patenting because of their overbroad effects. In contrast, the CAFC's
Myriad holding applies legal precedent and legislative intent more
accurately and preserves an imperfect system that is nonetheless generating
new cures for diseases each year. Rather than restrain the innovation of the
United States' biotechnology industry, this Note outlines several possible
solutions, focusing on careful exercise of march-in rights as enumerated
under the Bayh-Dole Act of 1980. These rights would grant additional
patent licenses to reasonable applicants when patent owners fail to alleviate
satisfactorily the general public's health and safety needs.10
1I. PATENTS
The basis for U.S. patent law is found in Article I, Section 8, Clause 8 of
the United States Constitution, which assigns to Congress the power "[t]o
promote the Progress of Science and useful Arts, by securing for limited
Times to Authors and Inventors the exclusive Right to their respective
Writings and Discoveries."11  Through this constitutional authority,
Congress has established 35 U.S.C. § 101, which defines what can be
patented. The statute reads: "Whoever invents or discovers any new and
useful process, machine, manufacture, or composition of matter, or any new
and useful improvement thereof, may obtain a patent therefor, subject to the
conditions and requirements of this title."' 2
The wording of the statute is intentionally broad.13 How then has our
society gone about granting monopoly rights to inventors?l4 While the
10. 35 U.S.C. § 203 (2006).
I1. U.S. CONsT. art. 1, § 8.
12. 35 U.S.C. § 101.
13. DOJ Brief, supra note 4, at 11. See also Bilski v. Kappos, 130 S. Ct. 3218, 3225
(2010).
14. Letter from Thomas Jefferson to Isaac McPherson (Aug. 13, 1813), in 13 THE
WRITINGS OF THOMAS JEFFERSON 326, 333-34 (Andrew A. Lipscomb & Albert E. Bergh
eds., 1903). Thomas Jefferson was himself an inventor, and as the United States' first
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modem patent system covers a broad range of inventions and techniques, the
modem "boundary between eligible and non-eligible subject matter is
defined, in significant part, by the settled principle that the patent laws do
not embrace laws of nature, physical phenomena, or abstract ideas." 5 There
are two categories of patent claims at issue in Ass'nfor Molecular Pathology
v. United States Patent and Trademark Office ("Myriad I'): one set of
claims covers the BRCAl/2 genes, which are isolated or purified natural
compositions of matter, while the other set of claims covers the diagnostic
methods that utilize the isolated BRCA genes, which qualifies as useful
16processes.
The line of cases surrounding patent eligibility for compositions of matter
is a venerable one that stretches back a hundred years. In 1911, the
celebrated Judge Learned Hand held that a purified natural form of
adrenaline, or epinephrine, was patent-eligible subject matter.17 This holding
was followed by a Supreme Court decision that bacteria inoculants created
for leguminous plants that can take nitrogen from the air were patent
ineligible because, in the words of Justice Douglas, they were works of
nature "like the heat of the sun, electricity, or the qualities of metals."' 8 In
1958, however, the U.S. Court of Appeals for the Fourth Circuit held that a
product of nature could be patented when it is a "new and useful
composition of matter."' 9  Twenty-two years later, in Diamond v.
Chakrabarty, the Supreme Court came to a different conclusion when
considering whether man-made, genetically modified organisms designed to
Secretary of State (which encompassed many more powers than it does today), was
America's first patent examiner. One of Jefferson's most famous documents was a letter
to Isaac McPherson, in which he stated that there should be no patents on ideas. Id.
15. DOJ Brief, supra note 4, at 9. See also Diamond v. Chakrabarty, 447 U.S. 303,
308-309 (1980).
16. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriad l"), 653 F.3d 1329, 1334 (Fed. Cir. 2011).
17. MyriadH], 653 F.3d at 1352 (citing Parke-Davis & Co. v. H.K. Mulford Co., 189
F. 95 (C.C.S.D.N.Y. 1911)). Judge Lourie distinguished this decision from Myriad I by
making a distinction between isolated and purified compounds, although he noted that
Judge Hand found the purified adrenaline to be patentable subject matter. Id.
18. Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
19. Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156, 161 (4th Cir. 1958).
See also The Patent Act, 35 U.S.C. § 101 (1958).
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break down components of crude oil, could be patented.20 The Court held
that the microorganisms were patentable subject matter because "the claim is
not to a hitherto unknown natural phenomenon, but to a non-naturally
occurring manufacture or composition of matter-a product of human
ingenuity 'having a distinctive name, character [and] use."' 21
In 2008, the CAFC considered patent process claims in Bilski v. Kappos,
and reiterated the test for diagnostic methods, also known as the "machine or
transformation" test.22 The test holds that "[a] claimed process is surely
patent-eligible under § 101 if: (1) it is tied to a particular machine or
apparatus, or (2) it transforms a particular article into a different state or
thing." 23 Unbeknownst to Judge Robert W. Sweet, who utilized the Bilski
test in Myriad I, on June 28, 2010, the Supreme Court decided the Bilski
24
case on appeal. In Bilski v. Kappos, the Court affirmed the CAFC decision
on the merits of the case, while relying on prior precedent to do so, and
explicitly rejected the use of the "machine or transformation" test as the sole
test for determining patentability.25 Commentators have noted that while the
opinion offers little clarity for determining whether a particular innovation
falls within Section 101, "[b]y refusing to state any particular rule or
categorical exclusion, the Court has almost certainly pushed Section 101
patent eligibility to the background in most patent prosecution and
litigation."
20. Chakrabarty, 447 U.S. at 309.
21. See Myriad II, 653 F.3d at 1374 (quoting Chakrabarty, 447 U.S. 309-310).
According to Judge Lourie, the Supreme Court distinguished Chakrabarty from Funk
Brothers by stating that the organism, because of Chakrabarty's efforts, had "markedly
different characteristics from any [bacterium] found in nature." Chakrabarty, 447 U.S. at
310.
22. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriadl"), 702 F. Supp. 2d 181, 233 (S.D.N.Y. 2010).
23. Id.
24. Bilski v. Kappos, 130 S. Ct. 3218, 3218 (2010).
25. Dennis Crouch & Jason Rantanen, Bilski v. Kappos, PATENTLYO.COM (June 28,
2010, 10:00 AM), http://www.patentlyo.com/patent/2010/06/bilski-v-kappos-business-
methods-out-software-still-patentable.html.
26. Id. Instead, it is anticipated that patent litigation should focus on whether the
invention is a novelty (§ 102), nonobvious (§ 103), and fully and particularly described (§
112). Id. (citing Bilski, 130 S. Ct. at 3225).
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Ill. THE SEARCH FOR BRCA AND THE MYRIAD DECISION
A. Genes, BRCA1/2, and Myriad Genetics
Although scientists were able to extract Deoxyribose Nucleic Acid (DNA)
as early as 1869, it was not until 1944 that scientists determined that DNA
served as the carrier for genetic information.27 In 1953, scientists James
Watson and Francis Crick published A Structure for Deoxyribose Nucleic
Acid, which posited the DNA double-helix structure. Dr. Crick
subsequently proposed the central principle of molecular biology: "(1)
information is encoded in a segment of DNA, i.e., a gene; (2) transmitted
through a molecule called RNA; and then (3) utilized to direct the creation
of a protein, the building block of a body." 29
Since these discoveries, knowledge of human genetics has expanded
rapidly. The Human Genome Project, an international effort that was
coordinated by the U.S. Department of Energy and the National Institute of
Health ("NIH") from 1990 to 2003, has identified approximately 20,000-
25,00030 genes in human DNA and more than 3 billion chemical base pairs
that make up human DNA. 31 As genetics research increased, scientists
discovered that genes exist in every cell in the human body, and that they not
only determine outward physical traits, but also influence health, longevity,
and the development of a multitude of harmful diseases.32 Breast cancer is
the most commonly diagnosed cancer in the world and is "the second
leading cause of cancer death for women in the United States." 33 BRCAl
and BRCA2 (Breast Cancer Susceptibility genes) are human genes known as
27. Myriad 1, 702 F. Supp. 2d at 192-93.
28. Id. at 193.
29. Id.
30. The National Center for Biotechnology Information puts the count at 23,688
genes. Id. at 208.
31. About the Human Genome Project, OAK RIDGE NATIONAL LABORATORY,
http://www.oml.gov/sci/techresources/Human_Genome/project/about.shtml (last visited
Sept. 23, 2011).
32. Myriad I, 702 F. Supp. 2d at 194.
33. Id. at 200.
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tumor suppressors. 34 Under normal circumstances, BRCA1 and BRCA2
genes ensure the stability of the cell's DNA and prevent uncontrolled cell
growth, but mutations of these genes have been connected to the
development of hereditary breast cancer and ovarian cancer.3 5 Inheriting a
mutation of BRCAl or BRCA2 greatly increases the risk of developing
breast or ovarian cancer: on average, an American woman has a twelve to
thirteen percent chance of developing breast cancer, but the risk for women
with BRCA mutations is between fifty to eighty percent.36
The system required to sequence genes is generally understood by
molecular biologists, yet "because sequencing requires knowledge of the
sequence of a portion of a target sequence, some ingenuity and effort is
required for the initial sequencing of a target DNA." The search for the
genes associated with breast cancer was an internationally competitive
38project that started in the 1980s. In 1991, Dr. Mark Skolnick partnered
with a venture capital group to found Myriad Genetics and received $55
million from the NIH to discover and sequence the BRCAl gene.39 In
August 1994, Myriad began filing patent applications for the isolated
BRCAl gene and associated diagnostic methods.40 In November 1995,
Myriad and a new group of research allies identified the BRCA2 gene and
Myriad filed patent applications for their findings on December 21, 1995.41
34. BRCAl and BRCA2: Cancer Risk and Genetic Testing, CANCER.GOV,
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA (last visited Sept. 23, 2011).
3 5. Id.
36. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriad IH"), 653 F.3d 1329, 1339 (Fed. Cir. 2011).
37. MyriadI, 702 F. Supp. 2d at 200.
38. Id.
39. Bryn Williams-Jones, History of a Gene Patent: Tracing the Development and
Application of Commercial BRCA Testing, 10 HEALTH L. J. 123, 129-131 (2002). The
rival research team, led by Dr. Francis Collins, also received a significant grant from the
NIH to pursue BRCA research. Myriad l, 702 F. Supp. 2d at 201.
40. Myriad II, 653 F.3d at 1339. The first patent was issued by the USPTO on
December 2, 1997. Id.
41. Myriadl, 702 F. Supp. 2d at 202.
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Myriad provides genetic testing for the BRCA1/2 genes for clinicians and
patients at a cost of $3,200 per test.42 Such testing has been very profitable
for Myriad: in 2008, it cost Myriad $32 million to provide the tests while the
resulting revenues brought in $222 million.4 3  Although Myriad's testing
costs less than certain genetic tests conducted at other facilities," four of the
plaintiffs in the Myriad I case stated that certain researchers, clinicians, and
pathologists have the resources necessary to sequence and analyze genes
such as BRCAl/2 at a lower cost than Myriad's testing.45 In Canada, which
does not recognize Myriad's patent, the BRCA testing costs patients a third
of what Myriad charges.46 Myriad has offered licenses to researchers in the
past, but those licenses have been qualified by significant limitations, and
Myriad has not hesitated to enforce its patent claims against infringers,
either through letters or actual lawsuits.47
Myriad has long sought Medicaid coverage for its genetic testing, but has
thus far been unsuccessful in 25 states.48 Myriad's financial assistance
program provides free testing to low-income and uninsured patients, but a
significant gap exists between women whose insurance carriers will pay for
42. Brendan L. Smith, Wrangling Genes: As the Law Changes and New Medical
Frontiers Open, the Dispute over Genetic Patents Intensifies, 95 A.B.A. J. 56, 57 (2009).
43. Myriad1, 702 F. Supp. 2d at 203.
44. Id. at 204.
45. The four plaintiffs are Haig Kazazian, M.D., Harry Ostrer, M.D., David
Ledbetter, Ph.D., and Ellen Matloff, M.S. Id.
46. Laura Eggertson, Ontario defies US firm's genetic patent, continues cancer
screening, 166 CAN. MED. Ass'N J. 413, 494 (2002), available at
http://www.cmaj.ca/cgi/content/full/166/4/494. The European Patent Office also waged a
seven-year fight with Myriad Genetics over whether the patent on Myriad's BRCA test
would be upheld. Andrew Pollack, Patent on Test For Cancer Is Revoked By Europe,
N.Y. TIMES, May 19, 2004, at C3, available at http://www.nytimes.com/
2004/05/19/business/technology-patent-on-test-for-cancer-is-revoked-by-
europe.html?ref-myriadgeneticsinc; see also Tura Ray, EPO's Decision to Amend
Myriad's BRCA1 IP May Create More Uncertainty for Euro Labs, GENOMEWEB (Dec. 3,
2008), http://www.genomeweb.com/dxpgx/epos-decision-amend-myriadE2%80%99s-
brcal-ip-may-create-more-uncertainty-euro-labs.
47. Myriadl, 702 F. Supp. 2d at 207.
48. Id. at 204.
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the genetic testing or can afford the out-of-pocket costs, and low-income and
uninsured women covered by the financial assistance program.49 Four of the
plaintiffs who brought suit against Myriad fell into this gap: Lisbeth Ceriani,
Patrice Fortune, Vicky Thomason, and Kathleen Raker all attempted to
obtain some form of BRCAI/2 testing from Myriad, only to learn that
Myriad would not accept their insurance coverage, and all were unable to
pay the full cost out-of-pocket.o
Confirmation of a BRCA mutation may be enough to destroy a person's
life as they knew it. It is because the increased cancer risk presented by
testing positive for BRCA mutations is so high that many women choose to
undergo radical, preventative surgery based solely on the information
provided by the Myriad test.51 Awareness of the danger of BRCA mutations
is slowly seeping into the public consciousness: in the new season of the
HBO series In Treatment, a character played by Debra Winger undergoes
testing for BRCAl because she is concerned about her hereditary
susceptibility to breast cancer. Because of the tremendous consequences
of testing positive for a BRCA mutation, Myriad has faced anger from
patients over the expense of the BRCA test, as well as its unwillingness to
allow other companies to offer confirmatory testing.
B. The Myriad Decisions
On May 12, 2009, a number of individuals and organizations brought suit
against the United States Patent and Trademark Office and Myriad
Genetics.53  Among the plaintiffs were medical associations such as the
49. Id.
50. Id. at 189, 204. However, Judge Lourie's subsequent opinion noted that
"inability to afford a patented invention" did not establish standing. Myriad II, 653 F.3d
at 1344 n.3.
51. Breast Cancer Prevention Trial To Require Fewer Participants, I ONCOLOGIST
NEWS BULLETIN 331, 331-34 (1996), http://theoncologist.alphamedpress.org/content/
1/5/331 .full.pdf+html.
52. In Treatment: Episode 80: Week 1: Frances (HBO television broadcast Oct. 25,
2010). Camille, from the Real Housewives of Beverly Hills, also tested positive for a
BRCA mutation and discussed it on the show. Steph H, Real Housewives of BRCA,
BLOGSPOT.COM (Nov. 12, 2010, 4:51PM), http://goodbyetoboobs.blogspot.com/2010/l1/
real-housewives-of-brca.html.
53. Myriadl, 702 F. Supp. 2d at 186.
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Association of Molecular Pathology ("AMP"), the American College of
Medical Genetics ("ACMG"), the American Society for Clinical Pathology
("ASCP"), and the College of American Pathologists. 5 4 The plaintiffs were
later joined by considerable amici curiae, including the powerful American
Medical Association ("AMA"). The plaintiffs sought to invalidate the
patents on the BRCA genes, as well as Myriad Genetics' patented BRCA
56testing process, arguing that human DNA is a product of nature. The
Myriad I case was one of first impression because no court had Yet
addressed whether isolated DNA molecules are patentable subject matter.
On March 29, 2010, Judge Sweet handed down the decision noting that
the question of how to harness the information encoded in our DNA
"presents difficult questions touching on innovation policy, social policy,
medical ethics, economic policy, and the ownership of what some view as
our common heritage."58 The district court found "all of the challenged
claims invalid under 35 U.S.C. § 101," holding "that the challenged
composition claims are directed to unpatentable products of nature, and that
the method claims, which covered MYriad's diagnostic test process, are
directed to unpatentable abstract ideas."
Products isolated from nature must possess "markedl' different
characteristics" in order to constitute patentable subject matter. However,
according to Judge Sweet, because DNA is a "multifunctional" physical
carrier of information for synthesizing molecules in other areas of the body,
it is a "physical embodiment of laws of nature," and is so "distinct in its
essential characteristics from any other chemical found in nature" that its
existence in an isolated form cannot alter either the "fundamental quality of
54. Myriad I, 702 F. Supp. 2d at 186-89. The plaintiffs also included health and
women's groups such as Breast Cancer Action and the Boston Women's Health Book
Collective, scientists who have been deprived of the opportunity to research the BRCA
genes, and a group of women whose insurance will not cover the BRCA tests, but who
lack the money to pay out-of-pocket. Id.
55. Id. at 190.
56. Id. at 184.
57. DOJ Brief, supra note 4, at 6.
58. Myriad l, 702 F. Supp. 2d at 193.
59. Id. at 233-237; see also DOJ Brief, supra note 4, at 7.
60. MyriadI, 702 F. Supp. 2d at 226.
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DNA as it exists in the body [or] the information it encodes."6'
Furthermore, Judge Sweet held that Myriad's methods for detecting BRCA
mutations in a patient were invalid because the steps for analyzing and
comparing gene sequences were deficient in constituting the specific
transformative steps necessary for patentability, and were little more than
data gathering.62 Thus, the court found that the patents on isolated DNA
sequences of genes and patent claims related to the analysis of DNA
sequences were invalid.
On October 22, 2010, Myriad Genetics and its allies filed their Notice of
64Appeal to the CAFC. Almost a year later, on July 29, 2011, the CAFC
handed down its Myriad II decision.65  Myriad argued that the plaintiffs
lacked standing because the parties "do not have adverse legal interests and
... [p]laintiffs have failed to allege a controversy of sufficient immediacy
and reality to warrant the issuance of a declaratory judgment."66 However,
Judge Alan D. Lourie, writing for the majority, concluded that Dr. Harry
Ostrer had established standing sufficient to maintain the suit against Myriad
because he intended to "immediately engage in allegedly infringing BRCA-
related activities" through clinical diagnostic testing. The CAFC also
61. Id. at 185, 228.
62. Id. at 145.
63. Dan Vorhaus, Breaking: District Court Rules Myriad Breast Cancer Patents
Invalid, GENoMICs L. REP. (Mar. 29, 2010), http://www.genomicslawreport.com/
index.php/2010/03/29/breaking-district-court-rules-myriad-breast-cancer-patents-invalid/.
64. Brief for the Appellants at 1, Ass'n for Molecular Pathology v. United States
Patent and Trademark Office ("Myriad 11"), 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-
1406), 2010 WL 4600106.
65. MyriadII, 653 F.3d at 1329.
66. Id. at 1343. It had been suggested by some commentators that the CAFC would
dismiss the entire case on standing grounds. John Conley & Dan Vorhaus, What We
Learned From The Myriad Oral Argument, GENOMic L. REP. (Apr. 5, 2011),
http://www.genomicslawreport.com/index.php/2011/04/05/what-we-learned-from-
myriad-oral-argument/.
67. Myriad II, 653 F.3d at 1344. However, this was a narrow affirmation of the
district court's decision to exercise jurisdiction. The women who lacked the money to
pay for BRCA testing were excluded, as were other doctors and organizations. Judge
Lourie held that "simply disagreeing with the existence of a patent or even suffering an
attenuated, non-proximate, effect from the existence of a patent does not meet the
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affirmed the district court's decision that Myriad's method claims for
analyzing DNA sequences are unpatentable because "such claims include no
transformative steps and cover only patent-ineligible abstract, mental
steps."68 Judge Lourie cited Bilski v. Kappos to emphasize the importance
of transformation to the patentability of method claims and found that in the
instant case, the claims "are instead directed to the abstract mental process of
comparing two nucleotide sequences."69
However, the CAFC overturned the district court's judgment and held
isolated DNA sequences to be patent eligible. Judge Lourie held that the
Chakrabarty and Funk Brothers Seed Co. v. Kalo Inoculant Co. decisions
created the analytical structure through which to evaluate the patent
eligibility of isolated DNA.70  Under such a framework, the difference
"between a product of nature and a human-made invention . . . turns on a
change in the claimed composition's identity compared with what exists in
nature."7' The CAFC concluded that BRCAI and BRCA2 are patentable
because they have a distinctive chemical identity from molecules that exist
72in nature. When Myriad chemically cleaved the BRCA genes "from their
chemical combination with other genetic materials," it created a distinct
chemical entity. 73 The district court had excluded DNA molecules from
patentability because both isolated and native DNA retained the same
information in its nucleotide sequence; Judge Lourie firmly rejected that
train of argument, holding instead that genes "are best described in patents
by their structures rather than their functions."74
Supreme Court's requirement for an adverse legal controversy of sufficient immediacy
and reality to warrant the issuance of a declaratory judgment." Id. at 1348.
68. Id. at 1334.
69. Id. at 1356.
70. Id. at 1351.
71. Id.
72. Id.
73. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriad Il), 653 F.3d 1329, 1377-80 (Fed. Cir. 2011).
74. Id. at 1353.
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Perhaps the one thing that can be stated with certainty regarding the gene
patenting controversy is that the Judge Lourie opinion is not the final word
on the patentability of genes, even at the CAFC level. Judge Kimberly A.
Moore's concurring opinion stated that isolated sequences identical to
naturally occurring sequences would present a "much closer case" with
respect to patentability, whereas Judge William C. Bryson's dissent would
have upheld the district court in concluding that DNA sequences isolated
from nature do not constitute patentable subject matter.76
The plaintiffs in Myriad can either request a rehearing en banc at the
CAFC or petition for certiorari at the Supreme Court. The Supreme Court
is likely to accept certiorari, given that it recently accepted certiorari in
Prometheus Laboratories, Inc. v. Mayo Collaborative Services, which
centered around whether the company's patent claims "are drawn to a
natural phenomenon . . . or . . . only to a particular application of that
phenomenon."77 There is also the possibility of Congress wading into the
controversy. As Judge Lourie's opinion made clear: "if the law is to be
changed, and DNA inventions excluded from the broad scope of § 101
contrary to the settled expectations of the inventing community, the decision
must come not from the courts, but from Congress." 78
IV. GENE PATENTING ON CAPITOL HILL
The battle in Federal Court is but one front of a determined campaign to
end "gene patenting." Many of the associations and groups that united to
challenge Myriad Genetics have also been active in Washington in an
attempt to pressure Congress to advance legislation banning gene patenting.
Prospects for concerted congressional action on the issue have been bleak
ever since the House Judiciary Committee failed to report the Genomic
Research and Accessibility Act ("GRAA") out of committee in the 110th
Congress, which met from January 2007 to January 2009.79 However, Judge
Sweet's Myriad decision reinvigorated both lobbying organizations and
75. Id. at 1366.
76. Id. at 1368.
77. Prometheus Labs. Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 1354 (Fed.
Cir. 2010).
78. Myriad II, 653 F.3d at 1373.
79. Genomic Research and Accessibility Act, H.R. 977, 110th Cong. (2007).
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supportive congressmen alike. Moreover, the sharp fight over the
Wasserman Schultz provision to the Patent Reform Act of 2011 indicates
that the debate over gene patenting is likely to remain contentious.
The organizations advocating for a ban on gene patents vary both in size
and political temperament. The American Civil Liberties Union ("ACLU")
has spearheaded the campaign in Washington by employin such grassroots
tools as a letter-writing campaign 82 and a Facebook group.8- The ACLU has
also been joined by groups with powerful clout in Washington, including the
84AMA. Former Congresswoman Elizabeth Holtzman is currently lobbying
on behalf of Bio-Reference Laboratories because that corporation's ability to
administer certain tests has been stymied by owners of gene patents
exercising exclusive licenses concerning those tests. In addition, several
conservative religious groups oppose gene patents "because they believe
80. Press Release, U.S. Representative Xavier Becerra, Rep. Becerra Applauds Court
Decision on Gene Patenting [hereinafter Becerra Press Release l] available at
http://becerra.house.gov/index.php?option=com content&view=article&id=412:rep-
becerra-applauds-court-decision-on-gene-patenting&catid=3:press-releases&Itemid-4.
81. See generally Letter from Laura W. Murphy, Director of Washington Legislative
Office, ACLU, and Michael W. Macleod-Ball, Chief Legislative & Policy Counsel,
ACLU, to U.S. Representative David Dreier et al. (June 15, 2011) [hereinafter Letter
from ACLU], http://democrats.judiciary.house.gov/sites/democrats.judiciary.house.gov/
files/documents/ACLUl10615.pdf; Letter from AMP et al. to Members of Congress
(June 20, 2011) [hereinafter Letter from AMP], http://www.amp.org/documents/
DSWAmendmentsOppositionLetter6-201 ICAPAMPRDK_cleanFINAL.pdf.
82. Tell Congress Your Genes Aren't For Sale, ACLU.ORG,
https://secure.aclu.org/site/Advocacy?cmd=display&page=UserAction&id=2281 (last
visited Dec. 14, 2011) [hereinafter Tell Congress].
83. Don 't Patent My Genes!, FACEBOOK.COM, http://www.facebook.com/
pages/Dont-Patent-My-Genes-Liberate-the-Breast-Cancer-Genes/I 11528515533018 (last
visited Dec. 14, 2011).
84. Press Release, ACLU, AMA, March Of Dimes And Others Support ACLU
Challenge To Patents On Breast Cancer Genes (Aug. 27, 2009), available at
http://www.aclu.org/free-speech womens-rights/ama-march-dimes-and-others-support-
aclu-challenge-patents-breast-cancer-ge.
85. Hon. Elizabeth Holtzman: Matters, HERRICK.COM, http://www.herrick.com/
sitecontent.cfm?pageid=15&itemid=10933&print=1&type=41&print-I (last visited Sept.
23, 2011).
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God has given us these genes, and they should not be parsed out for
patents." Michael Crichton, the late novelist, was an outspoken critic of
gene patenting: he lectured, published articles, and even wrote the novel
Next, set in a world where a rapacious biotechnology company has the legal
right to forcefully extract cancer-fighting cells from a man and his
progeny.88
These groups have found allies within the congressional ranks who share
the view that "gene patents aren't benign and never will be." 89 On February
9, 2007, Congressman Xavier Becerra, a member of the powerful Ways and
Means Committee, introduced H.R. 977, also known as the GRAA. One
of the original co-sponsors of the bill was former Congressman Dave
Weldon, M.D., effectively making the bill a bipartisan undertaking.9 1
Becerra and Weldon were also joined by five other Congressmen-all
Democrats. 92
86. Karen Kaplan, Gene Patents are the Talk of the Town Following Surprise Court
Ruling, L.A. TIMES.COM (Mar. 31, 2010, 8:28 PM), http://latimesblogs.latimes.com/
boostershots/2010/03/gene-patents-myriad-legal-analysis.html. The most prominent of
the religious groups opposed to genetic patenting is the Southern Baptist Convention,
which "base[s] their opposition in their belief that patenting human genetic material
wrests ownership from God and makes a commodity of human biological material."
Letter from ACLU, supra note 81. The Southern Baptist Convention is so opposed to
gene patents that it filed an amicus curiae brief in support of the plaintiffs in Myriad H.
See generally Brief for the Southern Baptist Convention as Amicus Curiae in Support of
Plaintiffs-Appellees and Arguing for Affirmance, Ass'n for Molecular Pathology v.
United States Patent and Trademark Office ("Myriad IF), 653 F.3d 1329, 1351 (Fed. Cir.
2011) (No. 2010-1406), 2011 WL 585712.
87. Michael Crichton, Patenting Life, N.Y. TIMES, Feb. 13, 2007, at A23.
88. Patrick Anderson, Freaking Out Over Gene Tinkering, WASH. PosT, Nov. 28,
2006, at C02, available at http://www.washingtonpost.com/wp-dyn/content/article/2006/
11/27/AR2006112701397.html.
89. Crichton, supra note 87.
90. Genomic Research and Accessibility Act, H.R. 977, 110th Cong. (2007).
91. Press Release, U.S. Representative Xavier Becerra, Rep. Becerra Votes to
Prohibit Genetic Discrimination, Urges Passage of Gene Patenting Ban (Apr. 30, 2008)
[hereinafter Becerra Press Release 2], available at http://becerra.house.gov/index.php
?option=com-content&task-view&id=258&Itemid=47.
92. H.R. 977.
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H.R. 977 is a relatively short and seemingly simple bill. Title 35 of the
United States Code deals with patents, and Chapter 10 of Title 35 addresses
the patentability of inventions. Six sections currently exist under Chapter
10,94 and Congressman Becerra's bill would add section 106, titled
"Prohibition on patent of human genetic material." 95 The proposed section
reads: "notwithstanding any other provision of law, no patent may be
obtained for a nucleotide sequence, or its functions or correlations, or the
naturally occurring products it specifies." 96 In terms of applicability, the bill
states: "the amendment made by subsection (a) shall not apply to a patent
issued before the date of the enactment of this Act." 97 Thus, while the
legislation would prohibit future gene patents, it is not retroactive and would
not invalidate previously issued patents.98 Patents are valid for 20 years
from the date that an application is originally filed; thus, if Congressman
Becerra's bill is signed into law, the human genome will become patent-free
in twenty years.99
In March of 2007, H.R. 977 was referred to the House Judiciary
Subcommittee on Courts, the Internet, and Intellectual Property.100 On
October 30, 2007, Congressman Howard Berman organized a hearing on the
issue entitled "Stifling or Stimulating: The Role of Gene Patents in Research
93. 35 U.S.C. §§ 100-105 (2006).
94. Id. The six sections are (§ 100) Definitions, (§ 101) Inventions patentable, (§
102) Conditions for patentability; novelty and loss of right to patent, (§ 103) Conditions
for patentability; non-obvious subject matter, (§ 104) Invention made abroad, and (§ 105)




98. Bipartisan Bill to End Gene Patents, WHOOWNSYOURBODY.ORG,
http://www.whoownsyourbody.org/genepatentbill.html (last visited Sept. 23, 2011).
99. However, any pending application would not be patentable whether the
application was filed 2 days or 19 years before passage of the Becerra bill. Id
100. James DeGiulio, The Genomic Research and Accessibility Act: More Science
Fiction than Fact, 8 Nw. J. TECH. & INTELL. PROP. 292, 296 (2010), available at
http://www.law.northwestern.edu/journals/njtip/v8/n2/6/.
1592011
160 The Journal of Contemporary Health Law and Policy Vol. XXVIII: 1
and Genetic Testing."10' The recommendations of the four members of the
biotechnology research industry called to testify were similar in just one
respect: though all "endorsed some type of gene patent reform, none
presented testimony in favor of the sweeping reform embodied" by
Congressman Becerra's bill.102 Apart from the hearing, no further action
was taken to advance H.R. 977, and because the bill was not favorably
reported out of Committee during the I 10th Congress, it was cleared from
the books and failed to become law. 0 3 Prospects for the passage of similar
legislation in the near future seem somewhat dim due to the departure of half
of the Congressmen who originally co-sponsored H.R. 977.
101. Id.
102. The four who testified were Marc Grodman, CEO of Bio-Reference
Laboratories; Jon Soderstrom, managing director of the Office of Cooperative Research
at Yale University and President-Elect for the Association of University Technology
Managers (AUTM); Lawrence Sung, a professor at the University of Maryland and
partner at Dewey & LeBoeuf LLP; and Jeffrey Kushan, who presented testimony on
behalf of the Biotechnology Industry Organization. Id. at 303-04. Professor Sung argued
for inoculating academic researchers and their institutions from patent infringement and
establishing a right to use patented technology for basic research. Id Jeffrey Kushan
argued that, in technical terms, a person's DNA already lies outside the realm of
patentability. Id. Jon Soderstom argued that there was currently no tragedy of the anti-
commons in the biotechnology industry. Id Marc Grodman's solution to gene patenting
involves the exercise of the march-in provision of the Bayh-Dole Act, which will be
addressed later in this Note. Id.
103. To become law, a congressional bill must be reported out of its assigned
Committee and be voted on favorably by the entire House of Representatives, also known
as the Committee of the Whole. The bill must then be passed by the Senate before it
comes to the President's desk for his signature or veto. See generally How OUR LAWS
ARE MADE, H.R. Doc. No. 110-49 (2007), http://www.gpo.gov/fdsys/pkg/CDOC-
I Ohdoc49/pdf/CDOC-1 Ohdoc49.pdf.
104. Congresswoman Carson passed away in late 2007. Rep. Julia Carson Dies of
Lung Cancer, MSNBC.coM (Dec. 15, 2007, 1:09 PM), http://www.msnbc.msn.com/
id/22272981/ns/politics-capitol hill/t/rep-julia-carson-dies-lung-cancer/. Congressman
Weldon retired in 2008. Chad Pergram, GOP Rep. Dave Weldon to Retire, Fox NEWS
(Jan. 25, 2008), http://www.foxnews.com/story/0,2933,32555 1,00.html. Congresswoman
Shea-Porter lost her seat in the 2010 midterm elections. Holly Ramer, Shea-Porter Plans
Another US House Run, ASSOCIATED PRESS (Apr. 15, 2011), http://articles.boston.com/
2011-04-15/news/29422422_1_democrat-carol-shea-porter-anti-incumbent-mood-small-
businesses.
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However, Judge Sweet's Myriad I decision breathed new life into the
efforts of legislators and interested groups in Washington attempting to ban
gene patenting. Congressman Becerra hailed Myriad I as representing a
"significant progress," but noted that the holding "does not prevent the U.S.
Patent and Trademark Office [USPTO] from issuing future patents."' 05
Congressman Becerra then announced his intention to reintroduce the
GRAA.106 The ACLU also created a section on their website where
interested parties can send an editable form letter requesting that their
members of Congress sign on as a co-sponsor of a reintroduced GRAA.lo7
The ACLU, AMP, and Breast Cancer Action ("BCA"), as well as other
like-minded groups, recently flexed their lobbying muscles in order to
scuttle a proposed provision by Congresswoman Debbie Wasserman Schultz
that would have allowed second opinion testing in genetic tests.
Congresswoman Wasserman Schultz is a breast cancer survivor, who, after
taking Myriad's genetic test and discovering that she carried the BRCA2
mutation, underwent seven major preventative surgeries, including a double
mastectomy and an oophorectomy.o10  Congresswoman Wasserman Schultz
was disturbed by the fact that there was no way to get an independent
confirmatory BRCA test, especially given the significant consequences to
women's lives as a result of testing positive for the BCRA mutation. 109
Congresswoman Wasserman Schultz's amendment to Congressman Lamar
Smith's "Manager's Amendment," entitled "Permitting Second Opinions in
Certain Genetic Diagnostic Testing," would have created a new section,
listed as Section 287(d) in the Patent Act, that would have enabled providers
to offer second opinion genetic tests without the fear of being subjected to
damages for patent infringement.110
105. Becerra Press Release 1, supra note 80.
106. Id.
107. Tell Congress, supra note 82.
108. 157 CONG. REc. H4433 (daily ed. June 22, 2011) [hereinafter Wasserman
Schultz Speech] (statement of Congresswoman Wasserman Schultz).
109. While Congresswoman Wasserman Schultz's personal experience with BRCA
testing undoubtedly influenced her decision to offer the amendment, she also noted that
patients lacked the option of confirmatory genetic tests for colon cancer, Parkinson's
disease and Alzheimer's disease, among others. Id.
110. See H.R. 1249, 112th Cong. (2011) (withdrawn amendment offered by
Congresswoman Wasserman Schultz), http://judiciary.house.gov/hearings/pdf/
Wasserman%20Schultz%2021%2OAmdt%20TEXT.pdf; see also Dan Vorhaus, House
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The reaction from the ACLU and its allies to this proposed change was
swift and negative. Letters were sent immediately to Congressmen
denouncing the Wasserman Schultz provision."' While the ACLU
supported the amendment's goal of allowing patients more testing options,
the ACLU maintained that the amendment "fail[s] to block all patent holder
objections to testing, fails to address the many other limitations on scientific
research arising out of the issuance of [gene patents], and risks allowing
gene patent holders to argue that Congress implicitly endorses the validity of
such patents."1 2 Faced with this determined opposition, Congresswoman
Wasserman Schultz backed down and introduced a new amendment, which
would eliminate the safe harbor provision and instead require the USPTO to
conduct a study on genetic diagnostic tests.113  The fight for legislation
banning or modifying genetic patents will likely continue well into the
future, because regardless of the ultimate outcome of the court battles,
"Congress will continue to loom in the background, with the ability at any
moment to completely rewrite the rules of the game."1 14
V. ORPHAN DISEASES AND ANTISENSE DRUGS
An orphan disease is so rare that it is not considered commercially viable
for a pharmaceutical company to develop a drug to treat it. Americans
afflicted with orphan diseases have suffered adverse consequences brought
on by a gradual increase of regulation by the Food and Drug Administration
Introduces Patent Reform Proposal to Permit Second Opinions in Genetic Diagnostic
Testing, GENoMIcs LAW REPORT (June 15, 2011), http://www.genomicslawreport.com/
wp-content/plugins/as-pdf/generate.php?post=6003; Letter from ACLU, supra note 81.
111. See generally Letter from ACLU, supra note 81; Letter from AMP, supra note
81.
112. Letter from ACLU, supra note 81, at 1. See also Dan Vorhaus, Update:
Proposed Second Opinion Safe Harbor for Genetic Diagnostic Testing Withdrawn,
GENOMICS LAW REPORT (June 16, 2011), http://www.genomicslawreport.com/index.php/
2011/06/16/update-proposed-second-opinion-safe-harbor-for-genetic-diagnostic-testing-
withdrawn/#more-6034.
113. Vorhaus, Update: Proposed Second Opinion, supra note 112. See also
Wasserman Schultz Speech, supra note 108.
114. Vorhaus, House Introduces Patent Reform Proposal, supra note 110, at 3.
115. Aronson, supra note 9, at 244.
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("FDA") over the course of the twentieth century."' 6 The Orphan Drug Act
of 1983 significantly alleviated many of these problems and provided an
impetus for a burgeoning pharmaceutical industry that includes the emerging
antisense technology field."' 7 However, the success of the Act was achieved
primarily by granting patent protection and limited market exclusivity to
new drugs and compounds, including those of modified genetic material.'
The movement to ban gene patenting potentially threatens both the
livelihoods of those who suffer from rare diseases and the future of the
pharmaceutical industry.
A. Orphan Diseases
The FDA began functioning as a modem regulatory agency in 1906, but
originally, it wielded little of the power it does today." This lack of power
changed following the horrific sulfanilamide tragedy of the mid-1930s,
which resulted in the deaths of over a hundred children.120 Because
manufacturers were not required to demonstrate the safety of their products,
the FDA was powerless to hold the offending company accountable for the
116. NAT'L ORG. OF RARE DISEASES, ORPHAN DRUG DEVELOPMENT CONFERENCE:
UNDERSTANDING THE HISTORY OF THE ORPHAN DRUG ACT [hereinafter HISTORY OF THE
ORPHAN DRUG ACT], http://www.rarediseases.org/docs/policy/OrphanDrugDevelopment
Conference.pdf.
117. Id.
118. DEP'T OF HEALTH & HUMAN SERVICES, OFFICE OF INSPECTOR GEN., THE ORPHAN
DRUG ACT: IMPLEMENTATION AND IMPACT 8 (2001) [hereinafter IMPLEMENTATION AND
IMPACT], http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf.
119. In United States v. Johnson, 221 U.S. 488 (1911), the Supreme Court held that
the agency could not even regulate or punish false therapeutic claims by drug
manufacturers. FDA History-Part 1, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
AboutFDA/WhatWeDo/History/Origin/ucmO54819.htm (last visited Sept. 23, 2011).
120. In the late 1930s, many Americans took sulfanilamide, a pill that was very
effective in combating bacterial infections, but was unpalatable and difficult to consume.
Linda Bren, Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on
History, FDA CONSUMER MAG., Mar.-Apr. 2001, available at
http://permanent.access.gpo.gov/lpsl 609/www.fda.gov/fdac/features/2001/201 _kelsey
.html. The S. E. Massengill Company tasked its chemist with creating a solvent that
would make sulfanilamide easier to consume, especially for children. Id Unfortunately,
the solvent turned out to be similar in content to antifreeze, and 107 people, mostly
children, were killed, along with the unfortunate chemist, who took his own life. Id.
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deaths, and it could only fine the company for "misbranding" its product. 121
The disaster and the FDA's lack of ability to regulate effectively or punish
the responsible company sparked public outrage, which led to the Food,
Drug, and Cosmetic Act, ("Act") passed by Congress in 1938. The Act
was later augmented by the 1962 Kefauver-Harris Amendments, passed after
the United States narrowly escaped another drug tragedy. 23 Under the 1938
law, manufacturers needed only to show that their drugs were safe, but the
Kefauver-Harris Amendments required manufacturers also to demonstrate
that the new drugs were effective.124
Unfortunately, even eminently reasonable laws passed by the government
to protect its citizens can sometimes have unintended side effects. In the
case of the Kefauver-Harris Amendments, proving efficacy significantly
escalated the cost of drug development.125 As a result, pharmaceutical
companies began "making decisions about which compounds they would
develop based not on scientific importance, but on the size of the potential
121. Id.
122. Under the Act, pharmaceutical companies were now required to label their drugs,
and to demonstrate to the FDA that the drug was safe before it could be marketed. FDA
History-Part II, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/WhatWeDo/
History/Origin/ucm054826.htm (last visited Sept. 23, 2011).
123. In the late 1950s, thalidomide seemed to be a wonder drug that caused no
hangover, was not habit-forming and yet was able to bring "a quick, natural sleep for
millions of people who had trouble drifting off, and . . . gave pregnant women relief from
morning sickness." Bren, supra note 120. The drug was marketed throughout Europe,
South America and Canada, but its introduction into the United States was delayed by an
FDA medical officer named Frances Oldham Kelsey. Id. Kelsey's concerns led her to
continually request more information from the pharmaceutical company seeking to
introduce thalidomide. Id. As a result of the 1938 law, the FDA had 60 days to review a
drug application, and if the medical officer was not satisfied that the application was
complete, it was considered withdrawn. Id. The company would then have to resubmit
the request with additional data, and the 60-day clock would begin running again. Id.
Kelsey's persistence delayed approval of the drug until November 1961, when a German
pediatrician determined that the birth of children with terrible deformities was directly
linked to thalidomide use by their pregnant mothers. Id. By then, more than 10,000
children in 46 countries had been bom with thalidomide-related deformities. Id.
124. Id.
125. HISTORY OF THE ORPHAN DRUG ACT, supra note 116.
The Future ofAntisense Drugs
,,126
market and the likelihood of larger returns on investments. By the
1970s, as the detrimental effects of the 1962 amendments became clear,
public attention turned to the plight of those suffering from the rare orphan
diseases, which were estimated to afflict around 20 to 25 million
Americans. 127 Several non-profit patient organizations successfully financed
research on treatments for certain rare diseases but were unable to find any
pharmaceutical companies willing to make the drugs commercially
available.128 The pharmaceutical industry denied that orphan drugs were
unaddressed by their companies and campaigned strongly against
government intervention, but a concerted publicity campaign elicited a
groundswell of support that led to passage of the Orphan Drug Act of
1983.129
The Orphan Drug Act provides four main incentives for companies to
research cures for orphan diseases: federal research grants for clinical
testing, a tax credit that covers half of the costs of clinical trials, exemption
from FDA drug application fees, and most importantly, 7-year market
exclusivity for orphan drug sponsors.13 0 Over the nearly three decades since
126. Id.
127. Estimates of those affected by rare diseases have shifted over time. The Orphan
Drug Act defines orphan diseases as those for which there are fewer than 200,000
patients in the United States, and in 1990 the NEW YORK TIMES estimated that about 10
million to 20 million Americans suffered from 5,000 rare diseases. Andrew Pollack,
Orphan Drug Law Spurs Debate, N.Y. TIMES, Apr. 30, 1990,
http://www.nytimes.com/1990/04/30/business/orphan-drug-law-spurs-debate
.html?src=pm. In 2001, the Office of Inspector General for the Department of Health and
Human Services stated that around 20 million Americans suffered from around 6,000 rare
diseases. IMPLEMENTATION AND IMPACT, supra note 118, at 5. See also M. ANGELES
VILLARREAL, ORPHAN DRUG ACT: BACKGROUND AND PROPOSED LEGISLATION IN THE
107TH CONGRESS (2001), http://www.policyarchive.org/handle/10207/bitstreams
/3490.pdf. By 2010, Pharmaceutical Executive magazine put the number of rare diseases
at 7,000, and the number of Americans afflicted at 25 million. Walter Armstrong,
Pharma's Orphans, PHARM. EXEC. (May 1, 2010), http://pharmexec.findpharma.com/
pharmexec/article/articleDetail.jsp?id=670568.
128. HISTORY OF THE ORPHAN DRUG ACT, supra note 116.
129. The publicity campaign included newspapers, magazine articles, and even the
television show Quincy with Jack Klugman. Id.
130. IMPLEMENTATION AND IMPACT, supra note 118. Without exclusive marketing
rights, other companies are barred from marketing their version of the drug unless they
can prove clinical superiority, which is difficult to do. Id. "Marketing exclusivity may
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its inception, the Orphan Drug Act has had its fair share of problems,
including insufficient funding and companies that use common disease
targets to develop orhan drugs that might have larger, more profitable
general applications. Despite these flaws, the Orphan Drug Act generally
has been considered a great success; since 1983, FDA has approved 353
orphan drugs and granted orphan designations to 2,116 other compounds.132
Among the drugs approved are those designed to combat multiple sclerosis,
cystic fibrosis, hemophilia, Gaucher's disease, HIV-related ailments, and
rare forms of cancer such as pancreatic cancer.'3 3  The future for those
suffering from orphan diseases seems brighter than ever before, thanks to
continued investment and research, as well as the promise of emerging
antisense drugs.
B. Antisense Drugs
Antisense drugs are tiny pieces of "DNA or RNA that are chemically
modified to engineer good drug properties," and are then introduced into the
body where they bind with messenger RNA.13 4 The exact science behind
antisense drugs is somewhat complex. Isis Pharmaceuticals, one of the
leading pioneers in antisense drugs, describes the production of a protein:
be the most motivating incentive provided by the Act. Without marketing exclusivity,
unpatentable products could face competition from lower-priced generic versions of the
drug." VILLARREAL, supra note 127, at 3.
131. The most infamous of these drugs is Botox, which was initially granted orphan
drug status for a condition that causes uncontrollable blinking, but has large general
cosmetic applications. Armstrong, supra note 127. Another problem has been a risk-
minimizing approach from pharmaceutical companies that prefer to develop follow-ons
to existing drugs. These follow-ons improve on the effectiveness and safety of existing
drugs, but drain funding for new drug research, which is a riskier investment proposition.
Id. See also Pollack, supra note 127.
132. HISTORY OF THE ORPHAN DRUG ACT, supra note 116.
133. IMPLEMENTATION AND IMPACT, supra note 118, at 7; VILLARREAL, supra note
127, at 4; Press Release, BioCancell, BioCancell Receives Orphan Drug Approval for
BC-819 as Treatment for Pancreatic Cancer (Aug. 15, 2010), available at
http://www.biocancell.com/press-releases/95-pancreaticorphandrugapproval.
134. Antisense Drugs, ISISPHARM.COM, http://www.isispharm.com/Antisense-
Technology/Antisense-Drug-Discovery-Platform/Antisense-Drugs.htm (last visited Sept.
23, 2011).
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Genes contain the information necessary to produce proteins. A
gene is made up of bases (Adenine, Thymine, Cytosine and
Guanine commonly referred to as A, T, C and G), which are linked
together to form a two-stranded structure that resembles a twisted
ladder, known as DNA (deoxyribonucleic acid). The nucleotides
on one side of the ladder interact with complementary nucleotides
on the other side of the ladder according to specific rules (A pairs
with T, C pairs with G), creating the ladder's rungs. This highly
specific nucleotide binding is called hybridization. The sequence
or order of these nucleotides establishes the cell's recipe for
making proteins. One of the DNA strands is called the sense strand
and the other is called the antisense strand.13 5
Two linked processes, transcription and translation, are required for
protein production.136  In transcription, an enzyme known as RNA
polymerase temporarily separates the ladder in order to read the DNA
code.137 The RNA creates the single-stranded messenger RNA ("mRNA"),
which "is responsible for communicating the genetic message found in DNA
to other areas of the cell so that protein production can take place."'38
Translation occurs when "the mRNA travels to the ribosome, which is the
cell's machinery that assembles proteins based on the instructions carried by
the mRNA."l 39 Abnormalities in translation and/or transcription can lead to
the overproduction of proteins, which is implicated or associated with many
diseases.140 It is prior to translation that antisense drugs come into play by
causing degradation of the mRNA before it reaches the ribosome.14 1 The
antisense drug will bind, or hybridize, to the mRNA and degrade it so that
135. Basic Science, ISISPHARM.COM, http://www.isispharm.com/Antisense-
Technology/Antisense-Drug-Discovery-Platform/Basic-Science.htm (last visited Sept.
23, 2011).
136. Id.
137. Matthew Kellam, Making Sense Out ofAntisense: The Enablement Requirement
in Biotechnology After Enzo Biochem v. Calgene, 76 IND. L.J. 221, 233-234 (2001).
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the ribosome cannot translate the nRNA into a functional protein.142 This
process can inhibit the production of roteins involved in the disease that the
antisense drug is created to combat. 14V
To understand the difference between conventional drugs and antisense
drugs, an apt comparison can be made between "smart" and "dumb" bombs.
Some conventional drug therapies can be likened to World War II-era
"dumb" bombs that target healthy and diseased cells alike. For example,
chemotherapy drugs act by killing cells that divide rapidly, which is one of
the main properties of cancer cells. Unfortunately, they also
indiscriminately attack normal healthy cells that also divide rapidly, such as
hair follicle cells, which is why loss of hair is commonly associated with
chemotherapy.144 By contrast, antisense drugs theoretically act like "smart"
missiles that can identify and destroy only the intended target. For example,
if a particular protein caused diseased cells to reproduce to form a cancer
tumor, an antisense drug could be designed to interfere with the mRNA of
that protein, which would interrupt the formation of the tumor without
causing the severe side effects associated with chemotherapy regimens.
Antisense drugs are beginning to make a significant impact in both the
pharmaceutical sector at large as well as the more specialized orphan drug
sector.145 Orphan drug status has been granted to medications designed to
142. Id.
143. Id.
144. Managing Hair Loss From Chemotherapy, CHEMOTHERAPY.COM,
http://www.chemotherapy.com/side-effects/other-side-effects/hair loss.html (last visited
Sept. 23, 2011).
145. OGX-01 1 is an antisense drug that is currently in Phase III trial testing. It is
designed to counteract prostate cancer. Dan Jones, The long march of antisense, 10
NATURE REvs. DRUG DISCOVERY 395, 401-402 (2011), available at
http://www.nature.com/nrd/journal/vl0/n6/ful/nrd3474.html. Mipromersen is an
antisense drug designed to combat coronary heart disease, and is currently in Phase III
trial testing. Genzyme, Isis announce results of two mipomersen phase 3 studies, NEWS
MEDICAL (Aug. 5, 2010, 04:55 AM), http://www.news-medical.net/news/20100805/
Genzyme-Isis-announce-results-of-two-mipomersen-phase-3-studies.aspx. Antisense
drugs designed to counteract high-grade glioma and HIV are being researched and
clinically tested. Phase II HIV Gene Therapy Trial Has Encouraging Results,
SCIENCEDAILY (Feb. 18, 2010), http://www.sciencedaily.com/releases/2010/02/
100218191736.htm. See also P. Hau et al., Results of G004, a phase Ib actively
controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent
anaplastic astrocytoma, 24 J. CLINICAL ONCOLOGY 1566 (supp. 2006).
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help those suffering from rare diseases such as amyotrophic lateral sclerosis
("ALS" or "Lou Gehrig's disease"), spinal muscular atrophy, homozygous
familial hypercholesterolemia, and transthyretin amyloidosiS.146  Antisense
drugs offer the afflicted the possibility of combating rare and deadly diseases
with limited harmful side effects.
The pharmaceutical companies that have invested in orphan drug and
antisense technology research have done so because of the promise of
profitable returns through market exclusivity and patent ownership. 147 The
Orphan Drug Act provides companies with incentives such as tax credits,
research grants, and market exclusivity, but utilizes only a limited amount of
taxpayer money to do so. 148 While the Orphan Drug Act has been successful
in incentivizing companies to develop new drugs, it is reliant on those
companies to make the necessary investments in research and development,
and the only real long-term rewards for these investments are patents and
market exclusivity for the drugs created. Without those spurs for investment
in drug research and clinical testing, which can usually span years, if not
decades, most pharmaceutical companies would likely be unwilling to
partner with the federal government to combat rare diseases. Thus, the
invalidation of patents relating to genetically modified material could have
serious adverse effects on pharmaceutical research and those suffering from
rare diseases.
146. Press Release, Isis Pharmaceuticals, Isis Announces ISIS 333611 Granted
Orphan Drug Status for Treatment of ALS (Dec. 13, 2007),
http://www.asktheneurologist.com/support-files/isispdfantisense.pdf. Press Release, Isis
Pharmaceuticals, Isis Reports Financial Results and Highlights for First Quarter 2011
(May 5, 2011), available at http://www.reuters.com/article/2011/05/05/idUS244089+05-
May-201 1+PRN20110505. Yael Waknine, New FDA Orphan Drugs: CellCept, ISIS
301012, 5-HMF, MEDSCAPE NEWS (June 9, 2006), http://www.medscape.com/
viewarticle/535806. Severe and Rare / Neurodegenerative Diseases, ISISPHARM.COM,
http://www.isispharm.com/Pipeline/Therapeutic-Areas/Neurodegenerative-Disease.htm
(last visited Sept. 23, 2011).
147. Isis Pharmaceuticals alone has made more than $395 million from its
"intellectual property sale and licensing program that helps support" its "intemal drug
discovery and development programs." Intellectual Property, ISISPHARM.COM,
http://www.isispharm.com/Antisense-Technology/Intellectual-Property.htm (last visited
Sept. 23, 2011).
148. Part of the reason that the NIH Office of Rare Diseases was created in 2002 was
due to congressional acknowledgement that funding for rare diseases has not increased
appreciably. Rare Diseases Act of 2002, Pub. L. No. 107-280, § 2, 116 Stat. 1988 (2002)
(codified at 42 U.S.C. § 283h).
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VI. ANALYSIS OF MYRIAD I/IAND THE GRAA
The sector of the American biotechnology industry that patents DNA,
both naturally-occurring and modified, faces attacks on two fronts: in federal
court, where Judge Robert Sweet's Myriad I opinion held that genes do not
constitute patentable subject matter, and in the halls of Congress, where
Congressman Becerra and his allies seek to pass a law that prohibits the
patenting of human genetic material. Both attacks indirectly implicate
antisense drugs, are dangerously overbroad in their conception, and thus are
ill-suited and inappropriate for dealing with this issue.
A. Myriad I and Antisense
1. Myriad I, Antisense, and the Law
Judge Sweet's Myriad I holding potentially threatened antisense drug
patents. The district court judgment pointed out the multifunctional nature
of genes: "[genes] are chemical substances . . . compounds, [and yet] they
are physical carriers of information." 49 All chemical compounds transfer
information in some fashion, but genes are unique because they direct "the
synthesis of other molecules in the body-namely proteins," which makes
them the "physical embodiment of the laws of nature-those that define the
construction of the human body." 50 Antisense drug patents seem to be
implicated by this terminology. After all, antisense drugs are merely pieces
of modified DNA and RNA that are specifically intended to affect the
synthesis of proteins within the human body. They also constitute the
physical embodiment of information and nature's laws. Moreover, the
chemically synthesized BRCAl/2 DNA is useful primarily for its ability to
bind selectively, or hybridize, to native or isolated BRCAl/2 DNA for
diagnostic purposes in much the same way as antisense drugs are designed
to bind to mRNA and cause a therapeutic effect.'
The CAFC's ruling on genetic patenting is more friendly to both antisense
drug development and the pharmaceutical industry in general. Under the
Lourie standard, the function of the antisense drugs could not be considered.
However, antisense drugs have a chemical identity that does not appear in
nature-they are instead modified far beyond their ordinary means in order
149. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriadl'), 702 F. Supp. 2d 181, 228 (S.D.N.Y. 2010).
150. Id.
151. Id. at 197.
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to target and inhibit disease. Thus, antisense drugs clearly fit within what
the DOJ describes in the Myriad brief as molecules that "generally do not
occur in nature, but are instead the synthetic results of scientists'
manipulation of the natural laws of genetics."' 52 It is highly unlikely that
antisense patents can be challenged successfully in court as long as the
Federal Circuit's position is upheld by the Supreme Court, which would
mean that the pharmaceutical industry could continue operating with
minimum disruption.
2. Myriad and the Facts on the Ground
Judge Sweet's Myriad II opinion admits that "the isolation of the
BRCAl/2 genes required considerable effort on the part of Myriad and its
collaborators as well as ingenuity in overcoming technical obstacles
associated with the isolation process." 5  That is an understatement. Under
the current patent system in the United States, the great rewards for
successful research are coupled with considerable risk and uncertainty.
Even under the 1983 Orphan Drug Act, "the first drug to obtain marketing
approval receives the exclusive marketing rights."' 5 4 If a company loses the
race for a patent, their investors have staked a significant amount of money
on research that results in no gain. For example, the research team under Dr.
Francis Collins that competed with Myriad Genetics to discover and patent
the BRCAI gene revuired considerable resources to compete, including a
sizeable NIH grant. 1 Myriad's success meant that the investors for the
Collins team received no return.' 56
Given the severe consequences of failure, patent-holders are justified in
making a profit off of their hard-won research. The prevalence of breast
cancer makes knowing whether one is genetically predisposed to contract
152. DOJ Brief, supra note 4, at 15.
153. Myriad l, 702 F. Supp. 2d at 202.
154. HISTORY OF THE ORPHAN DRUG ACT, supra note 116.
155. Myriad l, 702 F. Supp. 2d at 201.
156. It all worked out for Dr. Collins in the end, however. President Obama
nominated Collins to be the Director of NIH, and Collins was unanimously confirmed on
August 7, 2009. Press Release, U.S. Dep't of Health & Human Services, Secretary
Sebelius Announces Senate Confirmation of Dr. Francis Collins as Director of the
National Institutes of Health (Aug. 7, 2009), available at http://www.hhs.gov/
news/press/2009pres/08/20090807d.html.
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the disease a critical fact in today's society for both women and men. It is a
government's obligation to provide for its citizens, especially those groups
that are small and powerless enough to fall through the cracks of society;
and the Orphan Drug Act is a prime example of the United States attempting
to meet this obligation.
Unfortunately, it is not Myriad's social obligation to provide cheap,
universal testing for citizens. Myriad was a case of first impression for a
reason: of the 4,382157 genes patented in the United States, plaintiffs like the
AMP and ACMG deliberately chose to bring suit against the BRCA patents
in particular because Myriad is a disagreeable opponent. Myriad's
diagnostic tests are arguably inordinately expensive, especially considering
that BRCA testing is an important health issue that could have a tremendous
impact on the lives of millions of Americans. Among other issues, it should
be noted that despite the handsome profit Myriad has accrued from its
patents, it has neglected to pay agreed-upon royalties to the researchers from
the National Institute for Environmental Health Sciences ("NIEHS") who
co-invented the BRCAI patent. However, punishing Myriad's avarice by
invalidating human gene patenting would negatively impact more
scrupulous and honest patent-holders, as well as the patients who depend on
the innovation of the patent system for possible cures to deadly diseases.159
Judge Sweet stated "the identification of the BRCAl and BRCA2 gene
sequences is unquestionably a valuable scientific achievement for which
Myriad Genetics deserves recognition, but that is not the same as concluding
that it is something for which they are entitled to a patent." 60 The problem
157. Myriad 1, 702 F. Supp. 2d at 208.
158. Id. at 202.
159. One could posit a situation in which a medical test was so critical to the health of
the United States' citizenry, and the costs charged by a patent-holder such as Myriad so
overly expensive, that the United States government could exercise aggressive tactics
such as using its power of eminent domain to appropriate the intangible property of the
patents, with the stipulation that the patent-holder be reasonably recompensed. Although
the federal government has used the threat of compulsory licensure, as a tactic in the
past, an actual policy would be without precedent in the health care field, and would
require a greater societal consensus concerning the appropriate role of the United States
government in health care. Kevin Outterson, State Pharmaceutical Eminent Domain
Legislation, NAT'L LEGISLATIvE Ass'N ON PRESCRIPTION DRUG PRICES (Jan. 28, 2005),
http://www.reducedrugprices.org/read.asp?news=207. See also Matt Fleischer-Black,
The Cipro Dilemma, AM. LAW (Jan. 2002), available at http://www.law.com (archived).
160. MyriadI, 702 F. Supp. 2d at 232.
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with that line of reasoning is two-fold. First, without the incentive from a
limited period of market exclusivity provided by patents, companies will not
take the risk of investing capital on innovative research, and very few
products would be brought to market.' Second, Congress has not opposed
gene patenting; when given the chance to clarify its intentions through the
passage of the GRAA, it declined to do so. Judge Lourie was correct when
he stated that Congress, not the courts, should be responsible for changing
the law to exclude "DNA inventions" from patent eligibility.162
B. Antisense and Sensibilityl63 on the Hill
Congressman Becerra stated that he authored his legislation banning gene
patenting in order "to ensure patients' access to their own medical
information, reduce the costs of gene tests and increase scientific research
into personalized medicine."1 64 However, the broad nature of Congressman
Becerra's bill as applied to such a complex issue raises extensive concerns
because, as with the application of an untested drug, the effects can be
unpredictable. The GRAA may appear to be a simple answer to legitimate
concerns about the nature of gene patenting, but due to the extremely
overbroad scope of the bill, it could damage the American pharmaceutical
industry severely.
Groups favoring genetic patenting argue that what are being patented
actually are not genes, but instead "isolated and purified" genetic
sequences. 16 In his speech introducing H.R. 977, Congressman Becerra
denounced this argument as "pure wordplay."l66 Congressman Becerra went
even further in his press release when he declared that his "legislation gives
guidance to the [USPTO] on what is not patentable-in this case genetic
material, naturally-occurring or modified."16  It appears from the language
161. Id. at 211.
162. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("MyriadIl'), 653 F.3d 1329, 1355 (Fed. Cir. 2011).
163. Moukheiber, supra note 8.
164. Becerra Press Release 1, supra note 80.
165. 153 CONG. REC. E315 (daily ed. Feb. 9, 2007) (statement of Congressman
Becerra, on the introduction of the Genomic Research and Accessibility Act).
166. Id.
167. Becerra Press Release 2, supra note 91 (emphasis added).
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of the bill that, if passed, Congressman Becerra's legislation would cover
antisense drugs, which are, after all, only chemically-modified pieces of
DNA and RNA. Companies aggressively pursuing antisense technology
research would be devastated by such legislation.16 s
Citizens who suffer from rare diseases would also be ill-served by such a
law. Without the revenue provided by patents on modified genetic material,
pharmaceutical companies have little incentive to invest in research and
development. The overbroad scope of Congressman Becerra's bill does not
simply affect antisense drugs. Because it would prohibit any patents for "a
nucleotide sequence," critic and patent lawyer Kevin Noonan, who served as
amicus curiae on behalf of Myriad Genetics,'69 has suggested that patents on
"blood clotting Factor VIII, erythropoietin, hemoglobin, albumen, and
human growth hormone" would also be banned by H.R. 977.170
Apart from one congressional hearing three years ago, the GRAA has not
been extensively debated in Washington. It is highly probable that should
some form of the bill ever be favorably reported from the House Judiciary
subcommittee, numerous amendments would be debated and added, which
would hopefully lessen the destructive effect of the proposed bill from 2009.
The National Organization for Rare Disorders ("NORD") has developed a
moderate proposal for both sides of the gene debate to consider. NORD
"supports patents for genes that have been changed or engineered by
scientists to create a commercial use, and for commercial products
developed from genetic information, but not for genes as they exist in
nature."' 7' Similarly, the DOJ agrees with Judge Sweet that isolated DNA is
not patent-eligible but argues that isolated DNA subject to human
manipulation is patent-eligible.172 Although DOJ made this expostulation to
168. Basic Science, supra note 135.
169. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriad 1"), 702 F. Supp. 2d 181, 192 (S.D.N.Y. 2010); see also The Colbert Report,
supra note 1.
170. Kevin E. Noonan, The Continuing Threat to Human Gene Patenting, PATENT
Docs (Oct. 16, 2007, 11:52 PM), http://www.patentdocs.org/2007/10/the-continuing-
.html?cid=86709402.
171. NAT'L ORG. FOR RARE DISORDERS, GENE PATENTING: NORD POLICY POSITION 1,
http://www.rarediseases.org/docs/policy/GenePatenting.pdf.
172. DOJ Brief, supra note 4, at 9-10. See also Kevin E. Noonan, DOJ Tries to Be All
Things to All Constituencies in Myriad Amicus Brief PATENT Docs (Oct. 31, 2010, 11:54
PM), http://www.patentdocs.org/2010/10/doj-tries-to-be-all-things-to-all-constituencies-
in-myriad-amicus-brief.html.
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the Federal Court of Appeals as a matter of interpreting the law, such a
clarification could also be incorporated into a legislative revision. Finally,
the now-rejected Wasserman Schultz amendment, though it would have
created uncertainties and practical problems of implementation, represented
another sensible path forward that could have alleviated the worst abuses
associated with genetic patenting.1
There is one potential solution to the genetic patenting debate, which is,
while unorthodox, explicitly sanctioned by law. The Bayh-Dole Act of 1980
addresses patents achieved partially through the aid of federally funded
research, which includes Myriad's BRCA patents.1 74  Should the
government determine that the contractor has failed to take "or is not
expected to take within a reasonable time, effective steps to achieve practical
application of the subject invention," or if "action is necessary to alleviate
health or safety needs which are not reasonably satisfied by the contractor,"
the government is empowered to effectively march-in and grant additional
nonexclusive, partially exclusive, or exclusive licenses to responsible
applicants. 175
In the thirty-one years since Bayh-Dole was enacted, no federal agency
has ever exercised its authority to grant additional licenses because such a
tremendous exercise of power could have potential chilling effects on entire
industries. Marc Grodman, the CEO of Bio-Reference Laboratories, when
giving his testimony to Congressman Berman's hearing on Congressman
Becerra's bill in 2007, specifically proposed utilizing the march-in powers of
the Bayh-Dole Act in the context of the controversy over Myriad's gene
patents.176 Exercising the march-in power would be a difficult balancing
act: if used too often, it could freeze innovation or be used to punish
companies simply for making too much of a profit. However, if exercised
173. Among these uncertainties is whether the safe harbor provision applies to tests
with only one provider, and whether the provision would apply when a genetic diagnostic
test would be used for "therapeutic treatment selection." Vorhaus, House Introduces
Patent Reform Proposal, supra note 110.
174. 35 U.S.C. § 203 (2006); see also Myriad l, 702 F. Supp. 2d at 201-02.
175. 35 U.S.C. § 203. In addition to (1) a failure to take effective steps to achieve
practical application of the subject invention, a federal agency may also grant additional
licenses if the action is (2) necessary to alleviate health or safety needs, (3) necessary to
meet requirements for public use as specified by federal regulations, and (4) is necessary
if the patent holder breaches § 204, which requires that the subject invention be
manufactured substantially in the United States. Id.
176. DeGiulio, supra note 100, at 304.
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properly against only the most egregious companies, the march-in power
could encourage continued innovation while stemming the worst excesses of
the current patent system. It would be difficult to argue that reasonable
exercise of the march-in power is unfair or constitutes meddling federal
interference, considering that Myriad and other companies achieved their
patents through federal assistance. Use of the march-in powers would
protect antisense patents and obviate the need for any broad-based bill such
as the GRAA.
One of the most radical solutions to the gene patenting issue was offered
by the now-defunct Secretary's Advisory Committee on Genetics, Health
and Society ("SACGHS") for the Department of Health and Human
Services. SACGHS considered march-in rights but concluded that the
administrative process for exercising the march-in rights was burdensome,
detailed, and time-consuming. 77  Instead, SACGHS recommended that
doctors and researchers simply be exempted from liability for infringement
of gene patents. Needless to say, this recommendation is extremely
controversial and has been denounced by many, including former Senator
Birch Bayh. 179 Thus, its chances of being enacted in the near future are
negligible.
Despite the recent resurgence of interest caused by the Myriad
controversy, passage of the GRAA or similar legislation in the near future is
extremely unlikely. The bill's sponsors have been whittled down through
deaths, retirements, and lost elections. Congressman Weldon's retirement in
2008 deprived the GRAA of its only Republican co-sponsor, and the
elevation of the Republican Party to the majority in the U.S. House of
Representatives for the 112th Congress makes it unlikely that Congressman
Becerra, a Democrat, will have more success in passing the bill than he did
in the previous two sessions, when the Democrats held the majority. It is
traditional political wisdom that the Republican Party is friendlier to
177. SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY,
REVISED DRAFT REPORT ON GENE PATENTS AND LICENSING PRACTICES AND THEIR IMPACT
ON PATIENT ACCESS TO GENETIC TESTS 69 (2010), http://oba.od.nih.gov/oba
/SACGHS/SACGHS%20Patents%20Report%20Approved%202-5-2001 0.pdf.
178. Dan Vorhaus, SACGHS Gene Patent Recommendations Still Controversial,
GENOMICs LAW REPORT (Feb. 8, 2010), http://www.genomicslawreport.com/index.php/
2010/02/08/sacghs-gene-patent-recommendations-still-controversial/.
179. Id.
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business and industry concerns. 80 Thus, it is highly unlikely that the GRAA
will be passed in the next two years unless conservative religious groups
demonstrate a far greater interest and involvement on the issue that goes
beyond mere statements of support for banning the patenting of God-given
genes.
Though the GRAA remains defunct for the present, the battle in
Washington over gene patenting will likely only intensify in the coming
years. The rejection of the Wasserman Schultz amendment by opponents of
gene patenting reflected unwarranted confidence in the outcome of the
Myriad appeal. With their position far less assured following Judge Lourie's
decision, the ACLU and its allies may be more open to embracing potential
legislative solutions that would give them most, but not all, that they seek.
While lobbying for moderate solutions like the NORD proposal, the
Wasserman Schultz amendment, or exercise of the Bayh-Dole march-in
rights might offer the greatest chance of success, it is also possible that these
groups will throw their weight behind radical proposals such as the
SACGHS solution or a renewed GRAA, even if that would take years to
pass. The future of the conflict over genetic patenting in Washington
depends on the Myriad opponents' assessment of the probability of success
in carrying their legal struggle all the way to the Supreme Court.
Even if Myriad II does not immediately incline gene patenting opponents
towards what they would see as legislative half-solutions, it must be noted
that Congress is not like the Executive branch, where Presidents have a
limited window to act upon their agenda for the country. It is not at all
uncommon for Congressmen to serve for more than a quarter of a century,
which affords them ample time to await the correct moment to pass laws that
reflect their long-cherished beliefs. 182 Congressman Becerra is a powerful
Congressman of considerable influence who may remain in Congress for
180. Corey Boles, Republican House Victory to Yield Business-Friendly Policies,
WALL ST. J. (Nov. 2, 2010, 10:05 PM), http://online.wsj.com/article/
SBl0001424052748704462704575591171988213264.html.
181. Karen Kaplan, Gene patents are the talk of the town following surprise court
ruling, BOOSTER SHOTS BLOG (Mar. 31, 2010, 8:28 PM), http://latimesblogs.latimes.com/
boostershots/2010/03/gene-patents-myriad-legal-analysis.html.
182. The longest-serving member of Congress is currently Congressman John Dingell
of Michigan, of whom it was once said that "he knew what he wanted in legislation and,
a hunter, he had a hunter's patience, the patience to wait in perfect stillness until the time
to strike . . . he could wait, and wait, and wait, through one session of Congress, through
an entire Congress, through another entire Congress." JOHN M. BARRY, THE AMBITION
AND THE POWER 203 (1989).
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quite some time, and the ACLU and affiliated organizations are similarly
powerful and dedicated.1 83 Thus, vigilance is required to protect against a
reprise of the GRAA or a similar bill, which could be so disastrously
overbroad as to deprive those who suffer from rare diseases of the antisense
research that might lead to cures.
VII. CONCLUSION
In his Myriad I opinion, Judge Sweet referenced a phenomenon known as
the "tragedy of the anti-commons," where "numerous competing patent
rights held by independent parties prevents any one party from engaging in
productive innovation."l 84  The recent tremendous advances made by
molecular biologists and pharmaceutical companies contradict this grim
prediction. The burgeoning antisense drug industry provides concrete
proof that the current patent system reasonably encourages innovation. The
greater danger lies instead in the possibility that, without the ability to profit
off of patents on modified genetic material, no company will be willing to
take the risk necessary to fund innovative research into new drugs and
treatments for illnesses. Those who will suffer the most from that possible
future are not only the pharmaceutical companies deprived of their lost
profits, but also those who are afflicted with rare diseases. Without the
ability to create any kind of revenue from patents, companies will stop
investing in research for cures to rare diseases because opportunities offered
by the Orphan Drug Act are more in the nature of incentives than a
substitute for revenue.
183. Congressman Becerra was first elected to Congress in 1992, but at age 52 is still
relatively young. See Biography, CONGRESSMAN XAVIER BECERRA,
http://becerra.house.gov/index.php?option=comcontent&view=article&id=13&Itemid=1
6 (last visited Nov. 23, 2011). Congressman Becerra is also a senior member of the
Ways and Means Committee, the most powerful committee in the House of
Representatives, and is also a member of the Democratic Leadership. Id
184. Ass'n for Molecular Pathology v. United States Patent and Trademark Office
("Myriad P), 702 F. Supp. 2d 181, 208 (S.D.N.Y. 2010).
185. From 1998 to 2007, the Research and Development programs of publicly traded
biotechnology companies has increased by over 60%, and from 1995 to 2005, the amount
of venture capital funding for biotechnology has increased by 300%. Ted Buckley, The
Myth of the Anticommons (May 31, 2007) (unpublished manuscript) (on file with the
Biotechnology Industry Organization), http://www.bio.org/ip/domestic/TheMythofthe
Anticommons.pdf.
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Given the intricacy and importance of the issues involved, and the distinct
possibility of severe and lasting disruption to the American biotechnology
industry, any potential reform or solution to the issue of genetic patenting
should be accomplished with the deftness and precision of a scalpel, as
possibly the march-in powers of the Bayh-Dole Act could. However, Judge
Sweet's Myriad I opinion and Congressman Becerra's proposed bill slash at
the issue like a broadsword. The United States DOJ, NORD, and
Congresswoman Wasserman Schultz's proposed amendment have advanced
potentially credible "third-ways" to navigate through the complexities of
molecular biology. However, before any reform can be contemplated, our
courts and Congress must adhere to the maxim that is the essence of the
Hippocratic corpus: first do no harm.' This has already been accomplished
in the courts, where Judge Lourie's decision preserved the status quo, and it
will hopefully be upheld should Myriad I's plaintiffs appeal the case to the
Supreme Court. In Washington, there are a multitude of potential ways to
address any problems with genetic patenting, but some proposals, such as
the Genomic Research and Accessibility Act, would cause so much harm to
America's pharmaceutical industry and those who suffer from rare diseases
that they must never be signed into law.
186. Cedric M. Smith, Origin and Uses of Primum Non Nocere-Above All, Do No
Harm!, 45 J. CLINICAL PHARMACOLOGY 371, 371 (2005).
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